The medicine ENTYVIO is owned by and made by Millennium Pharmaceuticals, Inc.
Vedolizumab, sold under the brand name Entyvio, is a monoclonal antibody medication developed by Millennium Pharmaceuticals, Inc. for the treatment of ulcerative colitis and Crohn's disease.
Entyvio was launched in both the U.S. and E.U. market in June 2014 and has been on the market for over 7 years in those countries.
Entyvio, from Takeda Pharmaceuticals, was first approved by the U.S. Food and Drug Administration (FDA) on May 20, 2014.
ENTYVIO (vedolizumab), an integrin receptor antagonist, is a humanized IgG1 monoclonal antibody produced in Chinese hamster ovary cells that binds to the human α4β7 integrin.
ENTYVIO has an approximate molecular weight of 147 kilodaltons.
The FDA approved ENTYVIO based on evidence from two clinical trials in patients with moderate to severe ulcerative colitis.
The trials were conducted in 34 countries around the world.
Entyvio isn't a systemic immunosuppressant. (Systemic drugs affect your whole body.)
Entyvio has a selective effect on your gut. It doesn't affect your entire immune system.
Entyvio contains the drug vedolizumab. Vedolizumab isn't available as a generic drug.
It's only available as Entyvio.